{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-001113","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.363711+00:00","generated_at":"2026-05-28T09:09:49.007147+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cingulate completes final FDA-required food effect study for CTx-1301; NDA submission targeted mid-2025","bullets":["Completed food effect study for CTx-1301 (dexmethylphenidate) in 26 healthy adults using 50mg dose.","No serious adverse events reported; data readout on bioavailability with/without food expected Q2 2025.","Final FDA-required study before NDA submission, which is planned for mid-2025.","2022 study with 25mg dose already showed CTx-1301 can be taken with or without food.","CTx-1301 designed as once-daily stimulant for ADHD covering entire active day."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-001113","json":"https://secwatch.observer/filing/0001493152-25-001113.json","markdown":"https://secwatch.observer/filing/0001493152-25-001113.md","text":"https://secwatch.observer/filing/0001493152-25-001113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315225001113/0001493152-25-001113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315225001113/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T09:09:49.007147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}